You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Claims for Patent: 10,214,586


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,214,586
Title:PD-L1 antibodies
Abstract:The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
Inventor(s):Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
Assignee: Eli Lilly and Co
Application Number:US15/239,959

Details for Patent 10,214,586

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Celgene Corporation, A Bristol-myers Squibb Company ABECMA idecabtagene vicleucel Injection 125736 March 03, 2021 ⤷  Get Started Free 2036-08-18
Pfizer Inc. ABRYSVO respiratory syncytial virus vaccine Injection 125769 May 31, 2023 ⤷  Get Started Free 2036-08-18
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 May 18, 2016 ⤷  Get Started Free 2036-08-18
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 March 08, 2019 ⤷  Get Started Free 2036-08-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.